Physician profile
Kevin List
NPI 1316407612
$845.07
in general payments reported to CMS, 2019-2025
14 companies · $423 in 2025
The $423 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $232 · 2024: $190 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanos Medical | $135.76 | 2025 | On-Q Pump and Accessories |
| Hologic Sales and Service, LLC | $135.58 | 2024 | Aptima |
| Myriad Women'S Health, INC. | $117.56 | 2023 | Myrisk |
| Biogen, INC. | $112.00 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $88.51 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $60.73 | 2025 | |
| Exact Sciences Corporation | $54.30 | 2024-2025 | Cologuard Collection Kit |
| Mayne Pharma Commercial LLC | $28.95 | 2025 | |
| Dynavax Technologies Corporation | $24.20 | 2025 | Heplisav-B |
| Coopersurgical, INC. | $20.60 | 2025 | Paragard T 380a |
| Organon LLC | $18.99 | 2023 | Nuvaring, Nexplanon |
| Agile Therapeutics, INC. | $18.30 | 2023 | Twirla |
| Gynesonics, INC. | $15.26 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Shield Therapeutics INC | $14.33 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin List listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.